Apellis Pharmaceuticals CMO Sells Shares to Meet Tax Obligations Amid Mixed Revenue Performance
Caroline Baumal, Chief Medical Officer of Apellis Pharmaceuticals, sold nearly 1,900 shares recently to satisfy tax liabilities tied to vested Restricted Stock Units. Concurrently, Apellis reported preliminary 2025 U.S. product revenue figures that surpassed $680 million but fell short of some Wall Street expectations, prompting varied analyst reac…